dopamine antagonist
Enable an agent to recognise a dopamine antagonist, assess evidence for its receptor-blocking activity, and identify the conditions and constraints governing its investigation or use.
Bundle → Layer → Finding → Questions Filled
6 bundles · 11 layers · 18 findings · 28 questions
Class identity and boundaries Defines what qualifies as dopamine antagonism and how individual substances relate to the registered class.
Membership criteria
Establishes the evidence needed to apply the class label.
Direct receptor antagonism
Record whether evidence identifies antagonistic activity at a specified dopamine receptor rather than an indirect reduction of dopamine signalling.
- What operational definition of dopamine-receptor antagonism determines membership? definition
- What evidence distinguishes direct receptor antagonism from altered dopamine synthesis, release, storage or clearance? boundary
Entity and role
Separates the class, its member substances and the contexts in which those substances act.
Active species attribution
Link the activity claim to the tested chemical species and distinguish it from product names, formulations and precursor substances.
- Which chemical species was tested, and how is it linked to the named substance or medicinal product? provenance
- Does antagonism belong to the parent compound, an active metabolite or both? boundary
Receptor pharmacology Captures dopamine-receptor targets and the functional character of their inhibition.
Subtype and selectivity
Records activity across dopamine-receptor subtypes and relevant alternative targets.
Target profile
Maintain a receptor-specific profile that distinguishes measured inactivity from missing measurements.
- Which of D1, D2, D3, D4 and D5 have measured binding and functional activity? measurement
- Which comparable measurements establish selectivity over other dopamine subtypes and non-dopamine targets? measurement
Functional mechanism
Describes how the substance changes receptor responses under defined conditions.
Antagonist behaviour
Distinguish neutral antagonism, inverse agonism and contextual antagonism by a partial agonist, and qualify claims about competition and reversibility.
- What basal-activity and agonist-challenge measurements support the functional classification? measurement
- What experiments establish whether antagonism is competitive, surmountable and reversible? provenance
Assay evidence and comparability Records how antagonism was measured and what conclusions the measurements support.
Measurement context
Preserves the experimental details needed to interpret receptor activity.
Assay-qualified values
Attach each potency or affinity value to its method, biological system, endpoint and experimental conditions.
- What species, receptor construct or isoform, expression system and signalling endpoint were used? provenance
- What agonist concentration, incubation time, concentration range and uncertainty accompany the reported value? measurement
Evidence strength
Tracks traceability, replication and alternative explanations for apparent blockade.
Validated antagonism
Record source-supported results and controls that distinguish receptor antagonism from assay interference or loss of biological responsiveness.
- Which inspected primary sources and independent results support the activity claim? provenance
- What controls exclude cytotoxicity, assay interference or inhibition downstream of the dopamine receptor? boundary
Exposure and target engagement Connects receptor pharmacology to active-species availability at the relevant anatomical site.
Distribution to target
Records whether the active species reaches the proposed site of dopamine-receptor blockade.
Central and peripheral access
Distinguish central from peripheral exposure using measured distribution evidence and its limitations.
- What evidence establishes brain penetration or predominantly peripheral exposure under the studied conditions? measurement
- How do protein binding, transport and active metabolites affect unbound exposure at the proposed receptor site? measurement
Engagement over time
Relates exposure duration to measured receptor engagement and functional effects.
Occupancy and persistence
Keep receptor occupancy, functional blockade and effect duration distinct while recording evidence linking them.
- What receptor occupancy or other target-engagement measurements are available, at which sites and times? measurement
- What evidence links engagement to functional blockade, and how long does blockade persist after exposure declines? boundary
Applications and use constraints Connects dopamine antagonism to supported applications, safety evidence and limits on action.
Supported applications
Separates experimental utility, therapeutic evidence and authorisation for a named substance.
Use-specific evidence
Record the application and evidence supporting a role for dopamine antagonism without assigning every member the same uses.
- Which experimental or therapeutic applications are supported for this substance, and what evidence attributes their effects to dopamine-receptor blockade? provenance
- What current, jurisdiction-specific status and conditions govern the proposed use? action
Hazards and action limits
Records substance-specific hazards and distinguishes receptor-related effects from other mechanisms.
Mechanism-qualified risk
Assess documented motor, endocrine and other adverse effects with explicit attribution, exposure context and uncertainty.
- What evidence links observed motor or prolactin-related effects to dopamine-receptor blockade, and which hazards arise from other targets? provenance
- Which documented contraindications, interactions and monitoring requirements constrain a proposed use of the specific substance? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of dopamine antagonist this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these kinds and varieties hold for the sense of dopamine antagonist this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these identifiers and schemes hold for the sense of dopamine antagonist this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of dopamine antagonist this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these typical measurements hold for the sense of dopamine antagonist this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of dopamine antagonist this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these regional variation hold for the sense of dopamine antagonist this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of dopamine antagonist this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Physical world and living systems
- Entry kind
- thing
- Plane
- PHY
- Domain
- PHY.OBJ
- Other names and narrower kinds
- Dopamine D2 Receptor Antagonists
What it is Filled
A dopamine antagonist is a substance that binds to one or more dopamine receptor subtypes and inhibits their activation by dopamine.
In scope
- Dopamine-receptor antagonism as a functional basis for class membership
- Receptor subtype, potency, selectivity and assay-dependent activity
- Relationships between antagonistic activity, active chemical species and exposure
- Evidence supporting experimental or therapeutic roles
- Mechanism-related hazards and substance-specific restrictions
Out of scope
- Complete chemical identity, synthesis and manufacturing specifications for individual compounds
- Dopamine synthesis inhibitors, storage depleters and other indirect mechanisms considered independently
- Dopamine agonists and partial agonists without separately demonstrated antagonistic behaviour
- Finished medicinal products, packaging and supply-chain instances
- Patient diagnosis, prescribing decisions and individual treatment plans
Why it exists Filled
Enable an agent to recognise a dopamine antagonist, assess evidence for its receptor-blocking activity, and identify the conditions and constraints governing its investigation or use.
Distinguishing features Filled
- Class membership requires evidence of antagonistic activity at a dopamine receptor; merely reducing a dopamine-associated response does not establish direct receptor antagonism.
- Receptor binding alone establishes affinity rather than functional antagonism; a functional result or appropriately qualified pharmacological evidence is needed.
- A partial agonist can oppose dopamine under some conditions while retaining intrinsic activity, so contextual antagonism must be distinguished from classification as a neutral antagonist.
- Dopamine antagonist is a pharmacological class rather than a single chemical substance, formulation or therapeutic indication.
- Antagonism at one dopamine-receptor subtype does not establish equivalent activity across D1, D2, D3, D4 and D5 receptors.
What robots and AI may and may not do Filled
Must not
- Recommend, dose or adjust a dopamine antagonist for a particular person.
- Use these drugs to sedate or control a person without lawful medical authority.
- Downplay side effects such as movement disorders.
- Stigmatize people who take antipsychotic medicines.
Only with a human decision
- Any prescribing or treatment decision.
May
- Explain what dopamine antagonists are and their medical uses from reliable sources.
- Report prescribing information and warnings from regulatory labelling.
Moral aspects Filled
- Some of these drugs have been misused to restrain people, which is a serious violation of dignity.
- People with mental illness deserve accurate, respectful information.
Who is affected
- Patients
- People in care homes
- Families
Owners Filled
Steward
The prescribing clinician answers for each use; medicines regulators authorize products.
Master systems
- National medicines registers
Links to other meta-models Filled
parent
- Q461076 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.dopamine-antagonist
- Wikidata: Q3271533 (https://www.wikidata.org/wiki/Q3271533)
Direct properties required Filled
- Active entity: Links to parent compound, active moiety and relevant metabolites
- Dopamine-receptor target: D1, D2, D3, D4, D5; multiple targets; unresolved
- Functional activity classification: Neutral antagonist, inverse agonist, partial agonist with contextual antagonism, mixed or unresolved
- Binding affinity: Ki or Kd in nM, with receptor identity and assay conditions
- Functional antagonist potency: KB or IC50 in nM, or dimensionless pA2, with method and conditions
- Antagonism mechanism: Competitive, noncompetitive, other demonstrated mechanism or unresolved; reversibility recorded separately
- Receptor selectivity: Dimensionless affinity or potency ratios across named targets using comparable assays
- Site-of-action exposure: Unbound concentration in nM and tissue or compartment; unbound brain-to-plasma ratio where available
- Dopamine-receptor occupancy: Percent occupancy, with receptor, tissue, method and time after exposure
- Use and evidence status: Research reagent, investigational use, authorised use or other documented status; jurisdiction and date required
Recognition not applicable Not applicable
Not applicable
Dopamine antagonism is a pharmacological property that cannot be identified reliably from a substance's appearance or dosage form.
Capabilities and actions required Filled
- Assess whether a candidate substance qualifies as a dopamine antagonist under an explicit evidence standard.
- Compare receptor-subtype profiles using compatible binding and functional measurements.
- Trace an observed effect to dopamine-receptor blockade, alternative targets or unresolved mechanisms.
- Identify missing exposure or target-engagement evidence before extrapolating laboratory findings.
- Retrieve substance-specific use restrictions and safety evidence relevant to a proposed activity.
Hazards and failure modes required Filled
- Can cause movement disorders, sedation and hormonal effects.
- Inappropriate use in older people with dementia carries serious risks.
Standards and interfaces required Filled
- The Anatomical Therapeutic Chemical classification maintained by the WHO Collaborating Centre for Drug Statistics Methodology classifies medicinal dopamine antagonists according to their therapeutic and pharmacological roles.
Context of use required Filled
- Dopamine antagonists are encountered in pharmacological research and in medicines used for conditions such as psychotic disorders and nausea.
- Their uses depend on receptor selectivity, distribution in the body and the evidence supporting each individual substance.
Sources Filled
- Wikidata item Q3271533: dopamine antagonist - identity and sense of the item
- Wikipedia: Dopamine antagonist - general description of the item
Open questions
- Does the registry intend this entry to include all dopamine-receptor antagonists or a narrower conventional grouping centred on particular subtypes?
- Should inverse agonists and partial agonists with contextual antagonism be class members or linked neighbouring categories?
- What minimum functional evidence should qualify a substance whose public record reports only receptor binding or an inherited class label?
- Which existing Vercy models already own chemical identity, receptor pharmacology and medicinal-product constraints, and should be linked to avoid duplication?
- Which authoritative sources and comparable primary assays should establish the initial member set and resolve conflicting subtype or potency claims?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q3271533/spec.json